Indi Molecular Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$35M
- Investors
-
7
Indi Molecular General Information
Description
Developer of a fully synthetic class of therapeutic and molecular diagnostic agents designed to replace traditional antibodies. The company's protein-catalyzed capture (PCC) agents can be deployed as both a precision-targeted therapeutic and an in vivo positron emission tomography imaging agent, and this dual role is achieved through a shared chelation chemistry platform, enabling healthcare professionals to use application-specific therapeutic or imaging radionuclides to retain the PCC agent for the specific pathology.
Contact Information
Website
www.indimolecular.comCorporate Office
- 5877 Obama Boulevard
- Los Angeles, CA 90016
- United States
Corporate Office
- 5877 Obama Boulevard
- Los Angeles, CA 90016
- United States
Indi Molecular Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series B) | $35M | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 24-Jul-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 31-May-2017 | $11.5M | $14M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 10-Dec-2013 | $2.5M | $2.5M | Completed | Startup |
Indi Molecular Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Indi Molecular Comparisons
Industry
Financing
Details
Indi Molecular Competitors (12)
One of Indi Molecular’s 12 competitors is MetCure, a Venture Capital-Backed company based in Augusta, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MetCure | Venture Capital-Backed | Augusta, GA | ||||
| Deep Genomics | Venture Capital-Backed | Toronto, Canada | ||||
| RhabdoTec | Formerly Accelerator/Incubator backed | Frankfurt, Germany | ||||
| KalGen Laboratory | Corporation | Jakarta, Indonesia | ||||
| Zata Pharmaceuticals | Accelerator/Incubator Backed | Worcester, MA |
Indi Molecular Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Indi Molecular Patents
Indi Molecular Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220323614-A1 | Kras-specific cyclic peptides, compositions, and methods of using and making | Inactive | 02-Apr-2021 | ||
| WO-2022212947-A8 | Kras-specific cyclic peptides, compositions, and methods of using and making | Inactive | 02-Apr-2021 | ||
| US-11766414-B2 | Compositions, delivery systems, and methods useful in tumor therapy | Active | 03-Nov-2020 | ||
| US-20220211648-A1 | Compositions, delivery systems, and methods useful in tumor therapy | Active | 03-Nov-2020 | ||
| US-20240180856-A1 | Compositions, delivery systems, and methods useful in tumor therapy | Inactive | 03-Nov-2020 | A61K31/165 |
Indi Molecular Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Indi Molecular Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Legend Capital | Venture Capital | Minority | ||
| Sabey | Corporation | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Asset Management Ventures | Venture Capital | Minority | ||
| Baird Capital | PE/Buyout | Minority |
Indi Molecular FAQs
-
When was Indi Molecular founded?
Indi Molecular was founded in 2013.
-
Where is Indi Molecular headquartered?
Indi Molecular is headquartered in Los Angeles, CA.
-
What is the size of Indi Molecular?
Indi Molecular has 2 total employees.
-
What industry is Indi Molecular in?
Indi Molecular’s primary industry is Drug Discovery.
-
Is Indi Molecular a private or public company?
Indi Molecular is a Private company.
-
What is Indi Molecular’s current revenue?
The current revenue for Indi Molecular is .
-
How much funding has Indi Molecular raised over time?
Indi Molecular has raised $49M.
-
Who are Indi Molecular’s investors?
Legend Capital, Sabey, Alexandria Venture Investments, Asset Management Ventures, and Baird Capital are 5 of 7 investors who have invested in Indi Molecular.
-
Who are Indi Molecular’s competitors?
MetCure, Deep Genomics, RhabdoTec, KalGen Laboratory, and Zata Pharmaceuticals are some of the 12 competitors of Indi Molecular.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
